S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69

Dynavax Technologies Stock Forecast, Price & News

-0.29 (-2.21%)
(As of 01/21/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
2.38 million shs
Average Volume
1.86 million shs
Market Capitalization
$1.54 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive DVAX News and Ratings via Email

Sign-up to receive the latest news and ratings for Dynavax Technologies and its competitors with MarketBeat's FREE daily newsletter.

Dynavax Technologies logo

About Dynavax Technologies

Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Berkeley, CA.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$46.55 million
Book Value
$0.53 per share


Net Income
$-75.24 million
Pretax Margin




Free Float
Market Cap
$1.54 billion

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Social Links


Overall MarketRank

2.59 out of 5 stars

Medical Sector

91st out of 1,419 stocks

Pharmaceutical Preparations Industry

35th out of 685 stocks

Analyst Opinion: 3.3Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.9 5 -4 -3 -2 -1 -

Dynavax Technologies (NASDAQ:DVAX) Frequently Asked Questions

Is Dynavax Technologies a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Dynavax Technologies stock.
View analyst ratings for Dynavax Technologies
or view top-rated stocks.

How has Dynavax Technologies' stock been impacted by Coronavirus (COVID-19)?

Dynavax Technologies' stock was trading at $3.07 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, DVAX stock has increased by 318.9% and is now trading at $12.86.
View which stocks have been most impacted by COVID-19

When is Dynavax Technologies' next earnings date?

Dynavax Technologies is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Dynavax Technologies

How were Dynavax Technologies' earnings last quarter?

Dynavax Technologies Co. (NASDAQ:DVAX) announced its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the consensus estimate of $0.05 by $0.29. The biopharmaceutical company had revenue of $108.27 million for the quarter, compared to analyst estimates of $77.30 million. Dynavax Technologies had a negative trailing twelve-month return on equity of 3.73% and a negative net margin of 14.60%. During the same quarter last year, the company posted ($0.15) EPS.
View Dynavax Technologies' earnings history

What price target have analysts set for DVAX?

3 equities research analysts have issued 12-month target prices for Dynavax Technologies' stock. Their forecasts range from $19.00 to $28.00. On average, they anticipate Dynavax Technologies' share price to reach $23.50 in the next twelve months. This suggests a possible upside of 82.7% from the stock's current price.
View analysts' price targets for Dynavax Technologies
or view top-rated stocks among Wall Street analysts.

Who are Dynavax Technologies' key executives?

Dynavax Technologies' management team includes the following people:
  • Ryan Spencer, Chief Executive Officer & Director
  • David F. Novack, President & Chief Operating Officer (LinkedIn Profile)
  • Kelly MacDonald, Chief Financial Officer & Senior Vice President
  • Robert Janssen, Chief Medical Officer & SVP-Clinical Development (LinkedIn Profile)
  • John L. Slebir, Senior Vice President & General Counsel

What is Eddie Gray's approval rating as Dynavax Technologies' CEO?

13 employees have rated Dynavax Technologies CEO Eddie Gray on Glassdoor.com. Eddie Gray has an approval rating of 59% among Dynavax Technologies' employees. This puts Eddie Gray in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Dynavax Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (bmrn), (MDVN) (MDVN), Incyte (incy), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Matinas BioPharma (MTNB), First Solar (FSLR), Inovio Pharmaceuticals (INO) and ADMA Biologics (ADMA).

What is Dynavax Technologies' stock symbol?

Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."

Who are Dynavax Technologies' major shareholders?

Dynavax Technologies' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Chicago Capital LLC (4.78%), Russell Investments Group Ltd. (0.05%), AE Wealth Management LLC (0.04%), CAPROCK Group Inc. (0.02%), First Hawaiian Bank (0.02%) and Diversified Trust Co (0.02%). Company insiders that own Dynavax Technologies stock include Andrew A F Hack, David F Novack, David F Novack, Justin Burgess and Robert Janssen.
View institutional ownership trends for Dynavax Technologies

Which institutional investors are selling Dynavax Technologies stock?

DVAX stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., First Hawaiian Bank, and Cutler Group LP. Company insiders that have sold Dynavax Technologies company stock in the last year include Andrew A F Hack, David F Novack, Justin Burgess, and Robert Janssen.
View insider buying and selling activity for Dynavax Technologies
or view top insider-selling stocks.

Which institutional investors are buying Dynavax Technologies stock?

DVAX stock was purchased by a variety of institutional investors in the last quarter, including AE Wealth Management LLC, Nordea Investment Management AB, Juncture Wealth Strategies LLC, Chicago Capital LLC, CAPROCK Group Inc., Wedbush Securities Inc., and Diversified Trust Co.
View insider buying and selling activity for Dynavax Technologies
or or view top insider-buying stocks.

How do I buy shares of Dynavax Technologies?

Shares of DVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Dynavax Technologies' stock price today?

One share of DVAX stock can currently be purchased for approximately $12.86.

How much money does Dynavax Technologies make?

Dynavax Technologies has a market capitalization of $1.54 billion and generates $46.55 million in revenue each year. The biopharmaceutical company earns $-75.24 million in net income (profit) each year or ($0.35) on an earnings per share basis.

How many employees does Dynavax Technologies have?

Dynavax Technologies employs 245 workers across the globe.

When was Dynavax Technologies founded?

Dynavax Technologies was founded in 1996.

What is Dynavax Technologies' official website?

The official website for Dynavax Technologies is www.dynavax.com.

Where are Dynavax Technologies' headquarters?

Dynavax Technologies is headquartered at 2100 Powell Street Suite 900, Emeryville CA, 94608.

How can I contact Dynavax Technologies?

Dynavax Technologies' mailing address is 2100 Powell Street Suite 900, Emeryville CA, 94608. The biopharmaceutical company can be reached via phone at (510) 848-5100, via email at [email protected], or via fax at 510-848-1327.

This page was last updated on 1/23/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.